

THE REVIEW OF SECURITIES & COMMODITIES REGULATION

AN ANALYSIS OF CURRENT LAWS AND REGULATIONS
AFFECTING THE SECURITIES AND FUTURES INDUSTRIES

Vol. 59 No. 1 January 14, 2026

PART I — MANAGEMENT’S DISCUSSION AND ANALYSIS: A GUIDE TO SEC COMPLIANCE AND BEST PRACTICES

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) represents a critical component of corporate financial reporting, serving as the bridge between raw financial data and meaningful investor insights. As regulatory scrutiny intensifies and market dynamics evolve, companies must navigate an increasingly complex landscape of disclosure requirements whilst maintaining transparency and strategic clarity. As a two-part series, this guide examines current SEC guidance on MD&A preparation, explores emerging trends in regulatory commentary, and provides practical recommendations for enhancing disclosure quality. Drawing from recent SEC staff comments and regulatory developments, Part I offers actionable insights for improving MD&A effectiveness whilst ensuring compliance with evolving standards. Part II, to be published subsequently, will address specialized disclosure challenges and practical implementation guidance.

By Folake K. Ayoola *

I. INTRODUCTION

Registration statements and periodic reports filed under the Securities Act of 1933 and Securities Exchange Act of 1934 are required to include a section on Management’s Discussion and Analysis of Financial Condition and Results of Operations (commonly known as MD&A). Investors are focused on MD&A as they look to understand management’s narrative explanation of the financial conditions, results of operations, future trends and uncertainties, and other statistical data, making this an area that also frequently gets the attention of the Securities and Exchange Commission (“SEC”) staff. Enforcement and comment trends as well as regulatory guidance demonstrate the SEC’s continued focus on MD&A. This article discusses the issues most

frequently raised by the SEC staff and provides guidance to assist companies in preparing MD&A disclosure that is easier to follow and understand, and providing information that more completely satisfies the SEC’s enunciated principal objectives of MD&A.

II. REGULATORY FRAMEWORK AND CORE OBJECTIVES

A. Regulatory Development of MD&A: From 1968 to Present

The SEC’s commitment to MD&A quality spans over 50 years of rulemaking and enforcement, demonstrating that effective disclosure remains central to investor

**FOLAKE K. AYOOLA is a partner in Goodwin Procter LLP’s Washington DC office. With over a decade’s experience at the SEC’s Division of Corporation Finance, she has specialized experience in SEC regulatory and compliance matters, including those related to SEC reporting and compliance requirements. Her e-mail address is fayoola@goodwinlaw.com. The opinions expressed are those of the author and do not necessarily reflect the views of any past or present employers or clients, and the analysis herein is based upon publicly available information.*

FORTHCOMING

- **PART II: MANAGEMENT’S DISCUSSION AND ANALYSIS: A GUIDE TO SEC COMPLIANCE AND BEST PRACTICES**